Get all your news in one place.

100's of premium titles.
One app.

Get all your news in one place.

100's of premium titles. One news app.

The Latest Breaking News from FDA

Benzinga Before The Bell: Elon Musk's Kids, Apple's Potential Security Measure, Covid-19 Vaccine Wastage And Other Top Financial Stories Thursday, July 7

CNBC

Benzinga

What’s in your sports supplement? New paper warns of accidental doping

Murky federal regulations and misleading labeling practices make determining the true ingredients of sports supplements near impossible.

Inverse

Coinbase, Moderna And 56 Biggest Movers From Yesterday

Gainers Inspira Technologies Oxy B.H.N. Ltd. (NASDAQ: IINN) shares climbed 75.2% to close at $2.19 after the company announced it has developed a non-invasive blood sensor designated to alert real-time change in patients' clinical condition.

Benzinga

From analysis to the latest developments in health,
read the most diverse news in one place.

Pig heart transplant recipient died of heart failure

‘But we don’t consider this a setback,’ says doctor who co-led groundbreaking surgery

The Independent UK

AP News Digest 3 a.m.

Here are the AP’s latest coverage plans, top stories and promotable content. All times EDT. For up-to-the minute information on AP’s coverage, visit Coverage Plan at https://newsroom.ap.org.

The Independent UK

Omicron boosters could be here by fall

As viruses morph and adapt, there's a greater call for targeted vaccines and boosters

Salon

What's Going On With Altria Stock Today?

Altria Group Inc (NYSE: MO) shares are trading higher Wednesday after the U.S. Food and Drug Administration temporarily suspended the ban of Juul e-cigarette sales.

Benzinga

Read news from The Economist, FT, and more,
with one subscription

Sarepta Reports One Heart Inflammation Case In Duchenne Gene Therapy Trial

Sarepta Therapeutics Inc (NASDAQ:SRPT) shared new functional data across multiple studies from the SRP-9001 (delandistrogene moxeparvovec) program for Duchenne muscular dystrophy. SRP-9001 is an investigational gene therapy under development in partnership with Roche Holdings AG (OTC:RHHBY). Results from Cohort 1 demonstrated a 3.8-point improvement and 3.2-point improvement on the Duchenne functional scale 52 weeks after…

Benzinga

Coherus's Refiling For Head and Neck Cancer Candidate Accepted By FDA For Review

Coherus BioSciences (NASDAQ: CHRS) announced that the United States Food and Drug Administration (FDA) has accepted for review the Biologics License Application (BLA) resubmission for Toripalimab in combination with Gemcitabine and Cisplatin as first-line treatment for patients with advanced recurrent or metastatic nasophar

Benzinga

The Daily Biotech Pulse: FDA Decision On Biogen Alzheimer's Drug Due In January, FDA Reviews Roche's Lymphoma Candidate, Rare Pediatric Tag For Kazia's Pediatric Brain Cancer Candidate

Here's a roundup of top developments in the biotech space over the last 24 hours:

Benzinga

InflaRx's Stock Gains Following FDA Fast Track Status To Skin Disease Drug

The US Food and Drug Administration (FDA) granted a Fast Track designation to InflaRx’s (NASDAQ: IFRX) lead candidate Vilobelimab for the treatment of ulcerative Pyoderma Gangrenosum (PG).

Benzinga

Benzinga Before The Bell: FDA Temporarily Suspends Juul Ban, FTX Wants Bitcoin Derivatives, Voyager Digital Files For Chapter 11 Bankruptcy And Other Top Financial Stories Wednesday, July 6

CNBC Ben & Jerry’s Sues Parent Unilever On Israeli business Sale

Benzinga

Kazia Shares Shoot Higher As FDA Grants Rare Pediatric Disease Designation To Brain Cancer Candidate

The United States Food and Drug Administration (FDA) has awarded Rare Pediatric Disease Designation (RPDD) to Kazia Therapeutics’ (NASDAQ: KZIA) lead drug Paxalisib for the treatment of atypical rhabdoid / teratoid tumors (AT/RT).

Benzinga

FDA Temporarily Suspends Banning Order On Juul's E-Cigarettes

The FDA temporarily suspended its ban on sales of the popular e-cigarette maker Juul, backed by Altria Group Inc

Benzinga

Get all your
news in one place.

100's of premium titles.
One news app.

Benzinga

Alphabet, Dyne Therapeutics And 74 Biggest Movers From Yesterday

Gainers Enjoy Technology, Inc. (NASDAQ: ENJY) shares jumped 81.5% to close at $0.31 on Tuesday.

The Independent UK

AP News Digest 3 a.m.

Here are the AP’s latest coverage plans, top stories and promotable content. All times EDT. For up-to-the minute information on AP’s coverage, visit Coverage Plan at https://newsroom.ap.org.

Reason

The FDA Perversely Seeks To Make Both Cigarettes and Harm-Reducing Alternatives Less Appealing

The agency’s policies would boost the black market and smoking-related deaths.

The Independent UK

FDA temporarily suspends order banning Juul cigarettes

The Food and Drug Administration has issued an administrative stay on the order it issued last month for vaping company Juul to pull its electronic cigarettes from the market

Get all your
news in one place.

100's of premium titles.
One news app.

Reason

What's In A Name?

A doctrine by any other name would be just as major.

Benzinga

What Is The Role Of The FDA In Measures Taken By Hawaii Officials Against A CBD Company?

The Hawaii Department of Health (DOH) and Hawaii Department of Public Safety (PSD) conducted operations to execute search warrants and to embargo products at several retail stores including a CBD dispensary in Honolulu, reported

Benzinga

Tesla, Ra Medical Systems And 51 Stocks Moving In Tuesday's Mid-Day Session

Gainers Ra Medical Systems, Inc. (NASDAQ: RMED) shares jumped 69.6% to $0.5240 after the company announced it has received FDA 510(k) clearance for its DABRA 2.0 catheter.

Benzinga

Why Precigen Shares Are Gaining Today

Precigen Inc (NASDAQ:PGEN) has agreed to sell its subsidiary Trans Ova Genetics, an animal reproductive technologies company, to URUS, a holding company with cooperative and private ownership. The deal consideration includes $170 million in upfront cash and up to $10 million earn-out based on the performance of Trans Ova in 2022 and 2023. …

Benzinga

Dyne's Shares Gain After FDA Removed Clinical Hold On Muscular Disease Study

Dyne Therapeutics (NASDAQ: DYN) announced that the U.S. Food and Drug Administration (FDA) has lifted the clinical hold and cleared its Investigational New Drug (IND) application to initiate a clinical trial of its drug DYNE-25.

Benzinga

What's Going On With Dyne Therapeutics Shares Today?

Dyne Therapeutics Inc (NASDAQ: DYN) shares are trading lower by 5.42% to $6.81 after the company announced FDA clearance of its Investigational New Drug application for DYNE-251 for the treatment of Duchenne muscular dystrophy.

Benzinga

Titan Pharmaceuticals Gets FDA Clearance To Commence Opioid Disorder Study

The U.S. Food and Drug Administration (FDA) has cleared Titan Pharmaceuticals’ (NASDAQ: TTNP) Investigational New Drug (IND) application for the Phase 1 study of its drug candidate Nalmefene.

1 … 185 186 187 188

People

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.